Sex: F
Vaccine: RSV, TDAP
Symptoms: Immunoglobulin therapy, Magnetic resonance imaging head normal, Magnetic resonance imaging spinal normal, Paraesthesia, Respiratory distress
Clinical narrative: asthenia/weakness; paraesthesia/tingling of extremities; guillain-barre syndrome; progressive respiratory distress; throat clearing; coughing; dyspnoea/shortness of breath; hypoaesthesia/bilateral hand numbness; This is a spontaneous report received from a Consumer or other non HCP. Regulatory number: 2726879-1.  A 70-year-old female patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), on 11Dec2023 as dose number unknown, single (Lot number: HF7708) for immunisation; diphtheria vaccine toxoid, pertussis vaccine acellular 3-component, tetanus vaccine toxoid (BOOSTRIX), on 11Dec2023 as dose number unknown, single (Lot number: DH3AZ) for immunisation. The patient's relevant medical history included: "Hyperlipidemia" (unspecified if ongoing); "asthma" (unspecified if ongoing); "OSA (on CPAP)" (unspecified if ongoing); "OSA (on CPAP)" (unspecified if ongoing); "migraines" (unspecified if ongoing); "anxiety/depression" (unspecified if ongoing); "anxiety/depression" (unspecified if ongoing); "IBS" (unspecified if ongoing); "RLS" (unspecified if ongoing); "osteopenia" (unspecified if ongoing); "vitamin D deficiency" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Chronic back pain" (unspecified if ongoing). Concomitant medication(s) included: ATORVASTATIN oral; SYMBICORT; CALCIUM CARBONATE; CHOLECALCIFEROL; CELEXA [CELECOXIB] oral; VALIUM oral; LINZESS oral; MAGNESIUM; FISH OIL; PANTOPRAZOLE oral. Past drug history included: Cipro, reaction(s): "Allergies: Cipro". The following information was reported: COUGH (hospitalization, disability, life threatening) with onset 19Dec2023, outcome "not recovered", described as "coughing"; DYSPNOEA (hospitalization, disability, life threatening) with onset 19Dec2023, outcome "not recovered", described as "dyspnoea/shortness of breath"; GUILLAIN-BARRE SYNDROME (hospitalization, disability, medically significant, life threatening) with onset 19Dec2023, outcome "not recovered"; HYPOAESTHESIA (hospitalization, disability, life threatening) with onset 19Dec2023, outcome "not recovered", described as "hypoaesthesia/bilateral hand numbness"; RESPIRATORY DISTRESS (hospitalization, disability, life threatening) with onset 19Dec2023, outcome "not recovered", described as "progressive respiratory distress"; THROAT CLEARING (hospitalization, disability, life threatening) with onset 19Dec2023, outcome "not recovered"; ASTHENIA (hospitalization, disability, life threatening), outcome "not recovered", described as "asthenia/weakness"; PARAESTHESIA (hospitalization, disability, life threatening), outcome "not recovered", described as "paraesthesia/tingling of extremities". The patient was hospitalized for guillain-barre syndrome, respiratory distress, throat clearing, asthenia, cough, dyspnoea, hypoaesthesia, paraesthesia (start date: 20Dec2023, discharge date: 21Dec2023, hospitalization duration: 2 day(s)). The events "guillain-barre syndrome", "progressive respiratory distress", "throat clearing", "asthenia/weakness", "coughing", "dyspnoea/shortness of breath", "hypoaesthesia/bilateral hand numbness" and "paraesthesia/tingling of extremities" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: Magnetic resonance imaging: Negetive for obvious etiology; normal. Therapeutic measures were taken as a result of guillain-barre syndrome, respiratory distress. Clinical course: On 19Dec, pt reported shortness of breath, coughing, bilateral hand numbness, frequent throat clearing. Presented to hospital on 20Dec with progressive tingling of extremities, weakness. MRI spine and brain negative for obvious etiology. Patient had progressive respiratory distress so initiated treatment with high dose methylprednisolone and WIG for presumed Guillan Barre. Patient continued to have progressive symptoms so initiated Plex on 21Dec. The patient is taking immunoglobulin therapy. No follow-up attempts are possible.